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Background: Apixaban (5 mg BID), dabigatran
(available as 150 mg and 110 mg BID in Europe),
and rivaroxaban (20 mg once daily) are 3 novel oral
anticoagulants (NOACs) currently approved for stroke
prevention in patients with atrial ﬁbrillation (AF).
Objective: The objective of this study was to
evaluate the cost-effectiveness of apixaban against
other NOACs from the perspective of the United
Kingdom National Health Services.
Methods: A Markov model was developed to
evaluate the pharmacoeconomic impact of apixaban
versus other NOACs over a lifetime. Pair-wise indirect
treatment comparisons were conducted against other
NOACs by using ARISTOTLE (Apixaban for Reduc-
tion in Stroke and Other Thromboembolic Events in
Atrial Fibrillation), RE-LY (Randomized Evaluation
of Long-Term Anticoagulation Therapy), and
ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) trial results for the follow-
ing end points: ischemic stroke, hemorrhagic stroke,
intracranial hemorrhage, other major bleeds, clinically
relevant nonmajor bleeds, myocardial infarction, and
treatment discontinuations. Outcomes were life-years,
quality-adjusted life years gained, direct health care
costs, and incremental cost-effectiveness ratios.
Results: Apixaban was projected to increase life
expectancy versus other NOACs, including dabiga-
tran (both doses) and rivaroxaban. A small increase in
therapeutic management costs was observed with
apixaban due to projected gains in life expectancy
and lower discontinuation rates anticipated on apix-
aban versus other NOACs through lifetime. The192estimated incremental cost-effectiveness ratio was
£9611, £4497, and £5305 per quality-adjusted life-
year gained with apixaban compared with dabigatran
150 mg BID, dabigatran 110 mg BID, and rivarox-
aban 20 mg once daily, respectively. Sensitivity anal-
yses indicated that results were robust over a wide
range of inputs.
Conclusions: Although our analysis was limited by
the absence of head-to-head trials, based on the
indirect comparison data available, our model projects
that apixaban may be a cost-effective alternative to
dabigatran 150 mg BID, dabigatran 110 mg BID, and
rivaroxaban 20 mg once daily for stroke prevention in
AF patients from the perspective of the United King-
dom National Health Services. (Clin Ther.
2014;36:192–210) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key word: Stroke prevention, apixaban, cost-effec-
tiveness, atrial ﬁbrillation, new oral anticoagulant.
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Having atrial ﬁbrillation (AF) increases a person’s risk
of experiencing stroke almost 5-fold.1 Traditionally,
prophylactic treatment in this setting has been basedVolume 36 Number 2
G.Y.H. Lip et al.on vitamin K antagonists (VKAs), drugs that have
been in use for 60 years2 for their conﬁrmed
effectiveness in preventing thromboembolic events.3
However, the well-known challenges in managing
VKA therapy, such as monitoring requirements and
the risk of hemorrhages, have resulted in such therapy
being underused in the treatment of AF.4 Given this
context, the development of novel oral anticoagulants
(NOACs), such as dabigatran, rivaroxaban, and
apixaban, and their demonstrated efﬁcacy in clinical
trials have been encouraging with regard to
addressing the need for improved stroke prevention
treatments for patients with nonvalvular AF
(NVAF).2,5 Dabigatran, a direct thrombin inhibitor,
given at a dose of 110 mg BID, demonstrated non-
inferiority to warfarin in the primary end point of
stroke and systemic embolism coupled with a signiﬁ-
cantly lower risk of major hemorrhage.6 In addition,
dabigatran 150 mg BID was superior to warfarin in
the prevention of stroke and systemic embolism, with
rates of major hemorrhage similar to warfarin.
Rivaroxaban, an oral factor Xa inhibitor, was
noninferior to warfarin in the prevention of stroke
or systemic embolism, with no signiﬁcant difference
between the treatments in the risk of major bleeding.7
Apixaban, another oral factor Xa and the third
NOAC to receive European Union marketing
authorization for the prevention of stroke and
systemic embolism in AF,8 is the only oral
anticoagulant that has been shown to be superior to
dose-adjusted warfarin in terms of reduction in the
rates of stroke and systemic embolism, major bleed-
ing, and all-cause mortality.9
This evidence on NOACs underpins current guide-
lines from the European Society of Cardiology, which
recommend the use of these drugs as “broadly
preferable to VKA in the vast majority of patients
with NVAF.”10 These drugs also offer the potential
advantage of not requiring the anticoagulant moni-
toring needed for VKA therapy. The choice among
NOACs, however, is not clear; this choice requires
consideration of several practical issues, including
patient characteristics, tolerability, and health
economic outcomes.2,10,11 A key means of capturing
such elements is a cost-effectiveness analysis that
investigates how the differences in costs associated
with therapy relate to differences in beneﬁts. This
analysis can be conducted by using modeling techni-
ques, which are commonly accepted as validFebruary 2014approaches to understanding the health economic
consequences of different therapeutic alternatives.1
Of note, many such analyses have compared an indivi-
dual NOAC (ie, apixaban, rivaroxaban, dabigatran)
versus warfarin by using data from randomized
clinical trial data,13–19 and several studies included
all of the 3 NOACs from a US or Canadian perspec-
tive.20–22 Crucially, however, no previous study has
compared health economic outcomes bet-
ween the 3 NOACs by using indirect treatment
comparison data from a UK perspective conforming
the drugs with their European labels.
From a health care payer’s point of view, the
absence of such data is a major gap in the evidence
to inform decisions on resource allocation for NOACs.
In particular, it is important to know whether the
clinical advantages in terms of the efﬁcacy and safety
proﬁle of apixaban over warfarin, as observed in
randomized clinical trials, translate into health eco-
nomic beneﬁts, especially when compared with other
NOACs, without head-to-head clinical trial data. The
objective of the present study, therefore, was to assess
the cost-effectiveness of apixaban (5 mg BID) versus
the other NOACs (including dabigatran and rivarox-
aban) approved for stroke prevention in patients with
NVAF. The study was conducted from the perspective
of the United Kingdom National Health Service.
METHODS
This study involved construction and use of an
economic model to estimate long-term clinical and
economic outcomes for patients with NVAF treated
with apixaban, dabigatran, or rivaroxaban.
Model Design
The model used a Markov cohort approach. In the
context of this study, such a model would conceptu-
alize the course of AF by exploring what might happen
over time to a hypothetical cohort of patients with the
condition over a lifetime horizon. This analysis was
performed by representing the disease course in terms
of mutually exclusive health (or disease) states,12,23
such as NVAF without complications, NVAF with
stroke, or NVAF with bleeding, that the patients can
enter, remain in, or move (“transition”) between as an
approximation to potential real-life patient journeys.
Time in a Markov model is represented as a recurring
ﬁxed interval, known as the model cycle.12,23 It is
assumed that during each cycle, patients may remain in193
Clinical Therapeuticstheir current health state (eg, NVAF in Figure 1) or
experience an event (eg, ischemic stroke) that would
cause them to move to at most 1 subsequent state (eg,
ischemic stroke). The likelihood of each of these
outcomes is known as its transition probability. These
probabilities are built into the model and applied to the
cohort during each cycle to calculate how the patients
would be distributed between the thromboembolic and
bleeding health states at the end of the cycle. This
method in turn allows the model to calculate the
related health care costs and beneﬁts that will have
accrued for the cohort as time has elapsed in the model.NVAF
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structure for this study is shown in Figure 1. The
patient cohort is assumed to start in the NVAF health
state, and time continues to elapse in the model until
all the patients end up in the death state,12 with
calculation of the related accrued health care costs,
life-years (LYs), and quality-adjusted life-years (QA-
LYs) at the end of each model cycle. The cycle
duration of 6 weeks was chosen deliberately to
capture the possibility of events related to AF that
occur within such a short time frame. The health
states were either permanent, indicating that patientsVAF
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G.Y.H. Lip et al.remain in them until death, or transient, suggesting
that patients only spend some time in that health state
(eg, clinically relevant nonmajor bleeding, other major
bleeding, other intracranial hemorrhage [ICH]) before
returning to their immediately previous health state.
In each cycle, the cohort is subjected to risks (ie,
transition probabilities) of experiencing the following
events that are health states within the model: ische-
mic or unspeciﬁed stroke (referred to as “ischemic
stroke”); ICH (with a deﬁned percentage of these
events being assumed to be hemorrhagic stroke); other
major bleeds (major bleeds that are not ICHs and that
are further classiﬁed as being either gastrointestinal-
or nongastrointestinal-related bleeds); clinically rele-
vant nonmajor bleed; myocardial infarction (MI);
systemic embolism; other cardiovascular hospitaliza-
tion unrelated to the aforementioned events; or death.
Patients also have a deﬁned risk of discontinuing
their ﬁrst-line treatment, which would cause them to
transition to the “NVAF with subsequent aspirin
treatment state,” in which their risks of events in the
following cycle are updated to those deﬁned for their
second-line aspirin treatment. Patients can enter this
state after discontinuing their initial anticoagulant
treatment owing to either ICH, other major bleeds,
or other reasons unrelated to stroke, bleeding, MI, or
systemic embolism. In this article, “other ICH” refers
to ICHs that are not hemorrhagic strokes, with almost
all cases being subdural hematoma.
For patients who experience nonfatal stroke (both
ischemic and hemorrhagic) in the model, the severity
of these events is classiﬁed into 1 of 3 categories of
disability based on the modiﬁed Rankin Scale: mild,
0–2; moderate, 3 to 4; and severe, 5.24 Patients
experiencing their ﬁrst nonfatal stroke can
experience 1 recurrent stroke in subsequent cycles.
Those experiencing a recurrent stroke transition to the
most severe health state between primary and
recurrent strokes. Recurrent strokes are modeled as
permanent states (ie, patients in these states are
assumed to have no subsequent events until they
transition to the death state). Similarly, nonfatal MI
and systemic embolism are also modeled as permanent
health states accumulating decrements in utility and
additional costs over a lifetime.
Population
The population represented in the analyses com-
prised patients with AF suitable for VKA therapy. TheFebruary 2014speciﬁc patient characteristics of the cohort (Table I)
were matched to those of participants in ARISTOTLE
(Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation),9 a
study that had compared apixaban with warfarin in
patients with NVAF.
Comparators
The model allowed comparison of predicted out-
comes for the cohort with ﬁrst-line use of each of the
following NOAC regimens: apixaban (5 mg BID),8
dabigatran 110 mg BID, dabigatran dose as recom-
mended in the summary of product characteristics
referred to as “dabigatran 150 mg” (ie, starting with
150 mg BID and switching to 110 mg BID at the age
of 80 years),25 and rivaroxaban (20 mg once daily).26
Risk of Clinical Events
The rates of various clinical events in patients taking
apixaban were obtained from the ARISTOTLE trial.9
To represent the comparative risks of such events
for the other NOACs, hazard ratios (HRs) were
applied to the rates for apixaban. These HRs were
calculated by using an indirect treatment comparison
of data from the trials of 3 drugs using the method of
Bucher et al27 (see Supplemental Appendix A in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2013.12.011. In the absence of direct head-to-head
studies, these indirect comparison analyses assumed
that the treatment effect from NOACs was independ-
ent of patients’ baseline characteristics in the following
studies: ARISTOTLE9 (apixaban 5 mg BID vs
warfarin, dose-adjusted to maintain an international
normalized ratio [INR] of 2.0–3.0), the ROCKET-AF
(Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared With Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation) study7 (rivaroxaban 20 mg once daily vs
warfarin; INR, 2.0–3.0), and the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
study6 (dabigatran 110 mg BID vs dabigatran 150 mg
BID vs warfarin; INR, 2.0–3.0). Table I details the
absolute event risks, the comparative HRs for
dabigatran and rivaroxaban, and how patients
experiencing certain events on the different NOACs
would be distributed as to the severity or subtype of
the event in ARISTOTLE.9
Clinical event rates for patients in the “NVAF with
subsequent aspirin treatment” state (ie, those receiving195
Table I. Demographic characteristics and clinical event rates according to treatment.
Patient Characteristics
Characteristic Source Characteristic Source
Starting age, y 70 6 CHADS2 distribution
Gender CHADS2: 0–1 34.0%
6
Male 64.7% 6 CHADS2: 2 35.8%
6
Female 35.3% 6 CHADS2: 3–6 30.2%
6
Clinical Event Rates
Subsequent Aspirin (After
Discontinuation of
Initial Treatment)
Dabigatran
(110 mg)
Dabigatran
(150 mg)
Rivaroxaban
Apixaban
Rate of Events per
100 Patient- years Source
Hazard Ratio Versus Apixaban (95% CI)
Source
Stroke rate 0.981 3.453 *† 1.198 (0.878–1.635) 0.823 (0.593–1.141) 0.980 (0.723–1.328) ‡
Intracranial hemorrhage 0.330 0.322 6† 0.733 (0.428–1.257) 1.020 (0.619–1.681) 1.731 (1.082–2.770) ‡
Other major bleed 1.790 0.887 6† 1.205 (0.965–1.504) 1.371 (1.102–1.705) 1.463 (1.150–1.793) ‡
Clinically relevant
nonmajor bleed
2.083 2.936 *† 1.155 (0.986–1.354) 1.303 (1.113–1.526) 1.488 (1.261–1.755) ‡
Other treatment
discontinuation
13.177 *† 1.452 (1.309–1.611) 1.505 (1.357–1.668) 1.184 (1.083–1.294) ‡
Myocardial infarction 0.530 1.110 † 1.474 (0.958–2.269) 1.456 (0.948–2.238) 0.935 (0.635–1.375) ‡
Systemic embolism 0.090 0.400 † 1.000 1.000 1.000 Assumption§
Other cardiovascular
hospitalization
10.460 13.571 *† 1.000 1.000 1.000 Assumption§
Other death rate 3.0825 *† 1.000 1.000 1.000 Assumption§
Distributions and Probabilities by Treatment
Stroke severity
distribution
Mild (mRS 0–2) 53% 36% *† 35% 35% 49% 10,27
Moderate (mRS 3–4) 21% 38% *† 28% 22% 18% 10,27
Severe (mRS 5) 8% 15% *† 10% 8% 6% 10,27
Fatal (mRS 6) 18% 11% *† 27% 35% 27% 10,27
Hemorrhagic stroke
among intracranial
hemorrhage*
77% 55% 6† 64% 41% 57% 10,27
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Table I (continued).
Patient Characteristics
Characteristic Source Characteristic Source
Hemorrhagic stroke
severity distribution
10,27
Mild (mRS 0–2) 23% 7% *† 35% 35 49% 10,27
Moderate (mRS 3–4) 32% 20% *† 28% 22% 18% 10,27
Severe (mRS 5) 10% 27% *† 10% 8% 6% 10,27
Fatal (mRS 6) 35% 46% *† 27% 35% 27% 10,27
Gastrointestinal bleeds
among other major
bleedsǁ
38% 39% 6† 41% 49% 45% 10,27
Patients experiencing
dyspepsia
throughout
treatmenta
1.67% 1.58% 6,Assumption¶ 3.69% 3.53% 1.67% 10,27
Patients requiring
annual renal
monitoring
0.00% 0.00% Assumption¶ 19.40% 19.40% 0.00% 10,27
CHADS2 ¼ congestive heart failure, hypertension, ageZ75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism; mRS ¼ modiﬁed
Rankin scale.
*Supplemental Appendix B.
†Supplemental Appendix C.
‡Supplemental Appendix A.
§Where data was unavailable for novel oral anticoagulants, we assumed the same rate as for patients treated with apixaban and varied the inputs in the deterministic
sensitivity analysis.
ǁData for dabigatran and rivaroxaban were adjusted, using warfarin as a common arm, to the respective proportions observed in the ARISTOTLE (Apixaban for
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
¶Assumed same proportion as for aspirin ﬁrst-line as observed in the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) trial.
#Dabigatran requires annual renal monitoring for patients with moderate to severe renal impairment as per the summary of product characteristics,25 whereas this
monitoring is not required for apixaban and rivaroxaban. G.Y
.H
.
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Table II. Treatment switch on the occurrence of events.
Event
% of Patients Switching
Treatment
Subsequent
Treatment
Impact on Future
Transitions Source
Ischemic stroke or systemic embolism 0 (patients treated with
NOACs)
Warfarin No Clinical
opinion*
100 (patients treated with
second-line aspirin)
Hemorrhagic stroke or myocardial
infarction
100 No
treatment
No
Other intracranial hemorrhage 56 Aspirin Yes 28
Other major bleed 25 Aspirin Yes 29
Other treatment discontinuation
(unrelated to events modeled)
100 Aspirin Yes Clinical
opinion*
NOACS ¼ novel oral anticoagulants.
*Clinical opinion to advise the treatment patterns upon the occurrence of each event was solicited from 2 cardiologists who
were part of the research team (Drs. Lip and Dorian).
Clinical Therapeuticsaspirin after discontinuation of initial NOAC treat-
ment) were based on the analysis of a subgroup
of patients in the AVERROES (Apixaban Versus
Acetylsalicylic Acid to Prevent Strokes)30 trial who
had been previously prescribed, but discontinued,
VKA and were then treated with aspirin instead
(Table I). Assumptions about the effects of treatment
discontinuation on the occurrence of events are
presented in Table II. The risks of ischemic stroke,
bleeding, and MI were increased progressively by
a factor of 1.46,31 1.97,32 and 1.3033 per decade,
respectively, to account for the increased likelihood of
these events with aging.
The risk of recurrence postischemic or hemorrhagic
stroke was assumed to be the same with all treatments
and estimated to be 2.72 per 100 patient-years.34
Mortality
On the occurrence of each event, case-fatality rates
based on data from trials (Table I) were applied to
represent the risk of dying as a result of the episode.
The case fatality rates for MI were obtained from
published literature and estimated to be 10.8% in
male subjects and 15.6% in female subjects.35 Case
fatality rates for other ICHs, other major bleeds,
and systemic embolism were 13%, 2%, and 9.4%,
respectively. Estimates were pooled from the198AVERROES30 and ARISTOTLE9 trials and were
assumed to be the same for all treatments (see
Supplemental Appendix A and B in the online
version at http://dx.doi.org/10.1016/j.clinthera.2013.
12.011).
All-cause mortality rates for apixaban excluding
deaths attributable to stroke, bleeding, MI, and
systemic embolism were derived from the ARISTO-
TLE trial9 and were applied to the cohort during the
initial 1.8 years in the model (ie, a period matching the
trial duration). These were assumed to be the same for
the other NOACs. Beyond 1.8 years, mortality rates
were modeled based on age- and gender-speciﬁc
general mortality data in UK life tables.36 In
addition, an HR to account for the higher mortality
associated with the following conditions was applied
to the general life tables and to patients in each
respective health state: AF (excluding excess
mortality due to the events modeled), stroke,
systemic embolism, or MI events (Table III).Utilities
Utility inputs (Table III) were obtained from a UK-
based utility catalogue.37 The disutility associated
with the use of NOACs was assumed to be the same
as that for aspirin.38Volume 36 Number 2
Table III. Utility and mortality estimates for each health state.
Health State Utility (SE) Source
Hazard Ratios Versus
General Population (95% CI) Source
Nonvalvular atrial ﬁbrillation 0.7270 (0.0095) 37 1.34 (1.20–1.53) 39
Ischemic or hemorrhagic stroke
Mild 0.6151 (0.0299) 37 3.18 (1.82–4.92) 40–42
Moderate 0.5646 (0.0299) 37 5.84 (4.08–7.60) 40–42
Severe 0.5142 (0.0299) 37 15.75 (13.99–17.51) 40–42
Myocardial infarction
Females 0.6151 (0.0299) 37 4.16 (2.27–2.88) 43,44
Males 0.5646 (0.0299) 37 2.56 (3.44–5.03) 43,44
Systemic embolism 0.6265 (0.0299) 37 1.34 (1.20–1.53)
Transient Health States/
Anticoagulation Use Utility Decrement Source
Utility Decrement
Duration
Assumption*
Source
Other intracranial hemorrhage 0.1511 (0.0401) 37 6 weeks Clinical opinion†
Other major bleeds 0.1511 (0.0401) 37 2 weeks Assumption‡
Clinically relevant nonmajor bleeds 0.0582 (0.0173) 37 2 days Assumption‡
Other cardiovascular hospitalization 0.1276 (0.0259) 37 6 days Clinical opinion†
Treatment with new oral anticoagulants
or aspirin
0.0020 (0.00–0.04) 38 While on treatment
*In absence of data to inform the hazard ratio of mortality for patients with systemic embolism, we assumed patients with
systemic embolism would follow a similar mortality pattern to patients with nonvalvular atrial ﬁbrillation. This assumption
was tested in the deterministic sensitivity analysis.
†Assumptions around the duration of these utility decrements were derived upon discussion with 2 cardiologists who were
part of the research team (Drs. Lip and Dorian).
‡Assumptions based on Freeman et al.13
G.Y.H. Lip et al.Costs
Because the perspective adopted was that of the
United Kingdom National Health Service health care
payer, direct health care costs were included in the
analysis. Costs in the model are reﬂected in 2011
British pounds and are categorized as either acute care
costs relating to time spent in the hospital and
rehabilitation facilities (assumed to be 2 weeks in the
base case analysis described in the following discus-
sion) or maintenance costs applied to the remainder of
a patient’s lifetime (Table IV). Health and cost
outcomes were discounted at 3.5% per year.45
Analyses
The analyses compared apixaban with the other
NOACs in patients with NVAF suitable for VKA
treatment. Speciﬁcally, this analysis involved predict-
ing clinical and economic outcomes for a cohort ofFebruary 20141000 such patients over their lifetime, by calculating
the LYs, QALYs, and costs accumulated over this
period depending on which NOAC they were started
on. In the primary analysis (the base case), the
various predetermined data inputs described earlier
were used in the model. To assess whether potential
clinical advantages of apixaban over other NOACs
(as suggested by trial data) would be worth the
money spent on the drug, an incremental cost-
effectiveness ratio (ICER [additional cost per addi-
tional QALY gained]) was calculated for each com-
parison with the other 2 drugs. The ICER was then
compared with the commonly accepted UK payers’
willingness-to-pay threshold of £20,000 for each
QALY gained45 (ie, if the ICER of apixaban vs
other another NOAC was below this threshold,
then apixaban was considered a cost-effective treat-
ment alternative).199
Table IV. Resource use and unit costs.
Variable Cost, £ (95% CI) Unit Source
Daily cost of apixaban 2.20 10 mg daily dose 46
Daily cost of dabigatran 110 or 150 mg 2.20 220 or 300 mg daily dose 46
Daily cost of rivaroxaban 2.10 20 mg daily dose 46
Monitoring 20.69 (17–25) Per month 47
Dyspepsia 83.19 (48–129) Per year 46,47
Annual renal monitoring test 3.00 Per test 47
Event
Acute Cost, £
(per Episode)
Maintenance Cost, £
(per Month) Source
Ischemic and hemorrhagic stroke
Mild 6815.00 (5993–7410) 145.24 (86–200) 48
Moderate 6436.88 (5793–6870) 158.31 (98–216) 48
Severe 14,107.41 (12,589–15,166) 445.82 (375–200) 48
Fatal 9063.23 (7158–12,978) — 48
Other intracranial hemorrhage 3010.00 (2190–3456) — 47
Other major bleeds
Gastrointestinal bleeds 1493.68 (1237–1825) — 47
Nongastrointestinal-related 3947.92 (2508–4554) — 47
Clinically relevant nonmajor bleed 1133.93 (751–1284) — 47
Myocardial infarction 2018.84 (1596–2554) 6.45 (4–10) 47,49
Systemic embolism 6815.00 (5993–7410) 145.24 (86–200) Assumed to be the
same as mild stroke48
Other cardiovascular hospitalization 1570.89 (1140–1798) — 46
Clinical TherapeuticsThe sensitivity of the base case results was eval-
uated by conducting 1-way sensitivity analyses. These
consisted of varying the model parameters, using their
95% CIs, one by one, while keeping all others
constant and re-generating results to evaluate the
robustness of the model’s base case predictions in
relation to uncertainties in the model parameters.
In addition to 1-way sensitivity analysis assessing the
statistical uncertainty around the identiﬁed parameters,
further scenario analysis was conducted to test uncer-
tainties in structural assumptions as well as the plau-
sibility and relevance of certain input data. These
scenarios were determined by the 2 cardiologists that
were part of the research team (Drs. Lip and Dorian)
and speciﬁcally involved testing assumptions around
the following: (1) treatment discontinuation; (2) stroke
severity; (3) bleed severity; (4) costs and utilities of MI
in current practice; and (5) utility decrement for ICH.
In addition to these analyses, probabilistic sensitiv-
ity analyses were performed by running 2000 itera-
tions (or “simulations”) of a 1000-patient cohort200entering the model, with the values for key model
inputs being varied between each iteration. The
speciﬁc inputs for each iteration were obtained by
random sampling from probability distributions of the
parameters concerned. The fact that these inputs
varied between iterations meant that every iteration
would generate its own prediction of incremental costs
and effectiveness and therefore its own ICER. The
results of the probabilistic analysis were plotted on
scatter-diagrams depicting the additional gains in
QALYs, with apixaban compared with the other
NOACs (on the x-axis) against the additional costs
of the drug (on the y-axis). The probabilistic results
were also used to generate a cost-effectiveness accept-
ability curve (CEAC), representing the proportion of
simulations for which each treatment was the optimal
treatment option at a given willingness-to-pay thresh-
old. Warfarin and aspirin were included as treatment
alternatives in the probabilistic analysis to assess the
probability of apixaban being the most cost-effective
option among all drugs used for preventing stroke inVolume 36 Number 2
G.Y.H. Lip et al.routine practice for patients with AF. Data for
warfarin and aspirin are displayed in in the online
version at http://dx.doi.org/10.1016/j.clinthera.2013.
12.011.
RESULTS
Base Case Analysis
For a cohort of 1000 patients considered over their
lifetime, starting treatment with apixaban rather than
another NOAC was predicted to result in fewer
strokes (ﬁrst and recurrent ischemic and hemorrhagic
strokes), systemic embolisms, and cardiovascular-
related deaths (Table V). Patients treated with
apixaban were also predicted to experience fewer
major bleeds compared with dabigatran 150 mg andTable V. Base case results over lifetime: clinical events
adjusted life-years (QALYs), and costs per pat
Variable Apixaban Dab
No. of events (per cohort of 1000)
Ischemic stroke 229
Recurrent ischemic stroke 18
Hemorrhagic stroke 26
Recurrent hemorrhagic stroke 1
Systemic embolism 24
Myocardial infarction 84
Other intracranial hemorrhage 12
Other major bleed 165
Clinically relevant nonmajor bleed 287
Other cardiovascular hospitalization 1186
Other treatment discontinuation 635
Death
Event related 370
Other 631
Health outcomes (per patient)
LYs (undiscounted) 11.14
QALYs (discounted) 6.26
Costs (£ discounted per patient)
Anticoagulant and management 3555
Monitoring 106
Clinical events 5417
Total 9078
Incremental cost-effectiveness ratio
(apixaban vs comparator)
£ per QALY gained
February 2014rivaroxaban. However, compared with dabigatran
110 mg, apixaban increased the number of major
bleeds (ﬁrst and recurrent hemorrhagic strokes, other
ICHs, and other major bleeds) (15 episodes over the
lifetime horizon).
In terms of therapeutic management costs, com-
pared with dabigatran 110 mg, dabigatran 150 mg,
and rivaroxaban, respectively, apixaban yielded addi-
tional anticoagulant (drug) and management costs of
£713, £794, and £515 with average cost-offsets in
monitoring and clinical event–related costs (lifetime
reduction) of £249, £140, and £269; this led to a net
increment in total cost over a projected lifetime of
£464, £654, and £246. Apixaban’s additional beneﬁt
in reducing the number of various clinical events led toper 1000 patients, mean life-years (LYs), quality-
ient.
igatran 110 mg Dabigatran 150 mg Rivaroxaban
250 240 235
19 18 18
18 17 28
1 1 2
26 27 26
96 97 84
13 18 22
157 170 197
287 303 338
1178 1195 1187
715 729 668
396 388 381
603 612 619
10.96 11.02 11.06
6.16 6.19 6.21
2842 2761 3040
128 132 117
5644 5531 5675
8614 8424 8832
4497 9611 5305
201
Table VI. Scenario analysis: incremental cost-effectiveness ratio (ICER) of apixaban versus the comparator
(percent deviation from base case). Unless otherwise noted, values are 2011 British pounds.
Variable Dabigatran 110 mg Dabigatran 150 mg Rivaroxaban
Base 4497 9611 5305
Stroke severity independent of treatment 4824 (7.3%) 11,721 (22.0%) 5366 (1.2%)
Bleed severity independent of treatment 4157 (7.6%) 7135 (25.8%) 2835 (46.6%)
Stroke and bleed severity independent of treatment 4388 (2.4%) 8052 (16.2%) 2501 (52.9%)
Treatment discontinuation rates set to be the same
as apixaban after trial period (1.9 years)
2417 (46.3%) 9039 (6.0%) 3299 (37.8%)
Treatment discontinuation rates set to be 0 after
trial period (1.9 years)
3229 (28.2%) 8956 (6.8%) 3690 (30.4%)
No treatment discontinuation unrelated to stroke,
MI, SE, and bleeding events
412 (90.8%) 8596 (10.6%) 1308 (75.3%)
Assume no difference in relative efﬁcacy of MI 5050 (12.3%) 12,829 (33.5%) 5110 (3.7%)
MI utility increased (assumed to be the same as
that for patients with AF)
4811 (7.0%) 10,708 (11.4%) 5279 (0.5%)
ICH disutility increased to 0.3 4497 (0%) 9600 (0.1%) 5290 (0.3 %)
HR of mortality for AF set to 1 4178 (7.1%) 8515 (11.4%) 4908 (7.5%)
AF ¼ atrial ﬁbrillation; MI ¼ myocardial infarction; SE ¼ systemic embolism; ICH ¼ intracranial hemorrhage; HR ¼
hazard ratio.
Clinical Therapeuticsan additional 0.18, 0.12, and 0.08 undiscounted LY
and an additional 0.10, 0.07, and 0.05 discounted
QALY per patient, compared with dabigatran 110 mg,
dabigatran 150 mg, and rivaroxaban, respectively. The
result was the respective ICERs of £4497, £9611, and
£5305 per QALY gained (Table VI).
One-Way Sensitivity Analyses and Scenario
Analyses
Figures 2A through 2C present the results from the
sensitivity analyses for the top 15 parameters that had
the largest effect on the ICERs, in the order of their
respective inﬂuence. The statistical uncertainty around
model inputs not included on these tornado diagrams
had negligible impact on the ICER results. Table VI
presents the results of the scenario analysis around
structural uncertainties as well as the plausibility and
relevance of certain input data.
Compared with dabigatran 110 mg, the ICERs
from all sensitivity analyses and scenarios varied from
apixaban being dominant (ie, providing a higher
number of QALYs at a lower cost) to the drug being
associated with additional costs of £11,307 per QALY202gained (Figure 2A; Table VI). The comparison against
dabigatran 150 mg showed that the ICERs from all
scenarios varied from apixaban being dominant to its
incurring an additional £32,717 per QALY gained
(Figure 2B). In the comparisons between apixaban
and rivaroxaban, the ICERs from all scenarios varied
between apixaban dominating and being dominated
(Figure 2C), with the latter scenario occurring when
greater disutility was assigned to use of apixaban,
despite the drug’s anticipated advantage in relation to
bleeding and adverse events (Table I; see also
Supplemental Appendix A in the online version at
http://dx.doi.org/10.1016/j.clinthera.2013.12.011.
Compared with the other NOACs, the 4 scenarios
tested resulted in an ICER for apixaban above the
commonly accepted threshold of £20,00045 per
QALY: (1) increasing the disutility of treatment with
apixaban to 45 times that associated with other
NOACs (thus equaling the disutility for patients
treated with warfarin [ie, 0.013]); (2) decreasing
the ischemic stroke rate for aspirin used as second-
line therapy by 75% to 1.97 per 100 patient-
years, thereby beneﬁting treatments with higherVolume 36 Number 2
Figure 2. Results of the sensitivity analyses: (A) apixaban versus dabigatran 110 mg; (B) apixaban versus dabigatran
150 mg; and (C) apixaban versus rivaroxaban. Rates are displayed per 100 patient-years.The solid vertical
line represents the base case incremental costs per quality-adjusted life year (QALY) for apixaban
compared with the respective novel oral anticoagulant. Horizontal bars indicate the range of incremental
costs per QALY obtained by setting each variable to the values shown in the boxes while holding all other
values constant. HR ¼ hazard ratio; CV ¼ cardiovascular; ICH ¼ intracranial hemorrhage.
G.Y.H. Lip et al.
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Figure 3. Results of the probabilistic sensitivity analyses: (A) apixaban versus dabigatran 110 mg; (B)
apixaban versus dabigatran 150 mg; (C) apixaban versus rivaroxaban; and (D) cost-effectiveness
acceptability curves. Each line (A–C) represents a cost-effectiveness threshold representing the
maximum amount society is willing to pay for a quality-adjusted life-year (QALY) gain. Apixaban is
a cost-effective alternative in cases that fall to the right of this line; apixaban is not a cost-effective
alternative in cases that fall to the left of this line.
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G.Y.H. Lip et al.discontinuation rates; (3) decreasing the HR of stroke
for rivaroxaban in reference to apixaban to 0.72
(from 0.98 in the base case); and (4) increasing the
daily cost of apixaban to £2.64 at a 26% premium to
other NOACs.
Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis demonstrated that
apixaban was more effective at a small additional cost
versus other NOACs over a lifetime horizon (Figures
3A–3C). The ICER was below the commonly assumed
threshold of £20,000 per QALY gained45 in 98% of
trials comparing apixaban with dabigatran 110 mg, in
83% of trials compared with dabigatran 150 mg, and
in 85% of trials compared with rivaroxaban. The
results of the probabilistic analysis when all treatment
comparators were included are shown as multi-way
CEACs (Figure 3D). The CEAC, when generated by
using the data on outcomes with NOACs from the
indirect treatment comparisons and the data from
direct head-to-head comparisons against warfarin and
aspirin (see Supplemental Appendices B and C in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2013.12.011, indicated that apixaban was an optimal
treatment choice representing the maximum net
beneﬁt over aspirin, warfarin, and the other
NOACs, assuming payers are willing to pay £15,000
per QALY gained.
DISCUSSION
This study assessed the cost-effectiveness of apixaban
as a ﬁrst-line treatment in the prevention of stroke for
patients with AF eligible for treatment with VKA,
compared with other NOACs. Patients starting treat-
ment with apixaban were predicted to experience
fewer strokes and cardiovascular-related deaths com-
pared with those taking the other NOACs. Although a
cost-effectiveness analysis including comparisons of
NOACs versus warfarin for AF has recently been
published,20–22 our study seems to be the ﬁrst to be
conducted from a UK perspective, also incorporating
use of dabigatran as suggested by its European
label.25
Interestingly, an assessment limited to considera-
tion of the indirect comparison data would give a
favorable impression of dabigatran 150 mg compared
with apixaban in terms of reduction of stroke risk (ie,
HR versus apixaban ¼ 0.823); however, a broader
overall consideration of efﬁcacy, major bleeding, andFebruary 2014tolerability proﬁle extrapolated over a lifetime sug-
gests that apixaban therapy would result in fewer
strokes. This potential reduction in events (compared
with other NOACs) is attributable to: (1) a switch to
dabigatran 110 mg when patients reached age 80
years (as recommended by the summary of product
characteristics),25 where its protective effect was
poorer than apixaban (HR VS apixaban ¼ 1.198);
and (2) fewer patients discontinuing ﬁrst-line treat-
ment and starting second-line treatment (ie, aspirin) in
the apixaban arm because of fewer major bleeds and,
therefore, anticipated lower discontinuation rates.
Consequently, lower discontinuation rates and as-
sumed parity in drug acquisition costs resulted in
apixaban-treated patients gaining a stroke prevention
beneﬁt over a longer period in the model at a small
increase in pharmacologic treatment costs over the
lifetime horizon.
Bleeding outcomes were predicted to be less likely
with apixaban in general, except for a slightly higher
number of expected hemorrhagic strokes in the com-
parisons with dabigatran 110 mg and dabigatran 150
mg (27 vs 19 and 18, respectively [in the cohort of
1000 patients]), as well as a slight increase in the
number of other major bleeds compared with dabiga-
tran 110 mg (165 vs 157 [in the cohort of 1000
patients]). However, the overall beneﬁt of apixaban
outweighed these effects, as shown by an increase in
LYs and QALYs in comparisons with both dabigatran
and rivaroxaban in the analysis.
Our model was similar to those in earlier cost-
effectiveness studies assessing NOACs versus warfarin
or among each other that used a Markov approach to
represent potential stroke and bleeding events related
to AF over a patient’s lifetime.13,18–21,29 As with our
study, some of these other trials examined the impact
of treatment discontinuation.18–22,29,13 However, cau-
tion is needed when comparing their results with those
of our study, given the key differences in the study
designs. In the most recent published studies, which
compared all NOACs against warfarin and among
each other,20,21 dabigatran 150 mg was not modeled
according to the European label (ie, switching to 110
mg at age 80 years).25 Had we adopted a similar
approach, assuming patients remain on dabigatran
150 mg through their lifetime, apixaban would still be
expected to be cost-effective with an ICER of £9913
under the base case assumptions. In addition, treat-
ment discontinuation was not explicitly modeled.20,21205
Clinical TherapeuticsThis limitation, in addition to the others, could
account for the fact that these studies predicted (at
odds with ours) a slightly higher number of QALYs
gained in patients treated with dabigatran 150 mg
compared with rivaroxaban (the result of the study
excluding explicit modeling of treatment discontinua-
tion, which was lower in patients treated with rivar-
oxaban than those treated with dabigatran 150 mg).
By contrast, treatment discontinuation rates used in
our study were those observed in the clinical trials,
and the risk of further events in patients receiving
second-line treatment with aspirin were based on
secondary analysis of the subgroup of participants
in the AVERROES30 trial who had been
“demonstrated” to be unsuitable for VKA (rather
than “expected”) at randomization (42% of the trial
population). This approach allows more accurate
modeling of treatment patterns and the clinical event
risks in these patients, and is a key strength of our
study. Furthermore, results were robust to changes
around the assumptions of future treatment discontin-
uation rates. When setting treatment discontinuation
rates for rivaroxaban, dabigatran 110 mg, and
dabigatran 150 mg to equal those of apixaban
beyond the duration of the trial (ie, 1.8 years), the
ICERs decreased relative to the base case to £3296,
£2417, and £9614, respectively, due to increase in
costs among the NOACs arms; this outcome thus
demonstrates that the base case results presented are
conservative.
Additional important differentiators of our analysis
from previous work include its more detailed model-
ing of mortality. This analysis was conducted with the
use of mortality rates (for an initial period in the
model equivalent to the duration of the ARISTOTLE9
trial) and incorporation of an HR for increased
mortality (beyond this initial period) for patients
with AF compared with rates in the general
population (in both cases, excluding mortality due to
strokes, MI, and systemic embolism). Other models
have assumed that patients with AF who had not
experienced any events would follow mortality
patterns similar to the general population,3,18,21,29
despite clear published evidence indicating that mor-
tality of patients with AF is higher than that in the
general population, even after adjusting for mortality
rates due to stroke and MI.39,50 Our study’s incorpo-
ration of increased background mortality estimates
represents a more cautious modeling approach, in that206it reduced the predicted number of additional QALYs
gained from treatment, therefore leading to higher
estimates for the ICER (Table VI). Furthermore, we
included additional granularity and detail surrounding
the severity of stroke and bleeding events, allowing
these to be dependent on anticoagulant treatment
based on data from the trials. Although
ARISTOTLE9 highlighted apixaban’s favourable
impact in reducing the severity of stroke events,
potential differences in the severity of stroke events
between the NOACs is much less certain. The
assumption that ischemic stroke severity is
dependent on treatment may have favoured
apixaban. Had we assumed the same distribution of
mRS in patients experiencing stroke events, regardless
of treatment, the ICERs of apixaban versus the other
NOACs would increase however remain below the
£20,000 per QALY threshold.
As in previously published models,18,19,21 our study
included recurrent stroke events. However, in contrast
to these earlier studies, our analysis assumed that
NOACs would offer no additional prophylaxis for
secondary stroke prevention because published trials
of these treatments did not assess their efﬁcacy in
preventing recurrence of stroke. Consequently, recur-
rent stroke rates used in this study were assumed to be
the same for all treatments.34 Had we assumed that
the efﬁcacy of NOACs for secondary prevention is
equal to the efﬁcacy observed in primary prevention
similarly to earlier cost-effectiveness studies, the re-
sults are likely to have been favorable for apixaban,
given the lower number of strokes predicted in our
model using primary prevention efﬁcacy from the
trials.
Various limitations also apply to our analysis.
Although the utility estimates used in our study for
all events were obtained from the same source (a
standard EuroQol 5-Dimension catalogue) and vali-
dated by the 2 cardiologists who were part of the
research team (Drs. Lip and Dorian), allowing con-
sistent estimates between the various health states
represented in the model, several utilities may be
outdated with current practice. For example, the
evolution of MI would suggest a higher baseline utility
for these patients than those with a mild stroke;
however, setting the utility of patients with MI to
equal those with AF (ie, assuming no utility decrement
associated with MI) or setting the HR of MI for all
NOACs versus apixaban to 1 did not alter the modelVolume 36 Number 2
G.Y.H. Lip et al.conclusions (Table VI). Similarly, doubling the
utility decrement for ICH had a negligible impact on
results.
Importantly, event rates for each treatment were
derived from clinical trial settings, and, consequently,
the efﬁcacy and safety observed may not reﬂect real-
world outcomes. In the absence of head-to-head trials,
an indirect treatment comparison based on the published
NOAC studies was used to estimate the clinical event
rates for other NOACS. Although several earlier indirect
treatment comparisons have been conducted,51–54 we
performed further analysis to conform to model deﬁ-
nitions and requirements. However, similar to previ-
ously conducted indirect treatment comparisons, this
analysis did not control for the differences in patient
baseline characteristics, CHADS2 (congestive heart fail-
ure, hypertension, age Z75 years, diabetes mellitus,
prior stroke or transient ischemic attack, or throm-
boembolism) risk proﬁle, or time in therapeutic range.
Also, the comparison did not correct for key differences
between the designs of the trials, which was open-label
for RE-LY6 and double-blind for ROCKET-AF7 and
ARISTOTLE.9 This presents a fundamental challenge in
view of the heterogeneity of patient populations studied
in each study (eg, ROCKET-AF studied a higher-risk
population,7 and there was an open-label design in
RE-LY6 vs double-blinded comparisons in ROCKET-
AF7 and ARISTOTLE9). However, these variations seem
more likely to have favored the other drugs rather than
apixaban.
Lack of adjustment of baseline population charac-
teristics can be considered conservative favoring rivar-
oxaban. In an indirect comparison assessing treatment
effects among patients with a CHADS2 score Z3,
apixaban was found to reduce the risk of the primary
efﬁcacy outcome of stroke or systemic embolism by
23% compared with rivaroxaban (HR ¼ 0.77 [0.56,
1.06, 95% CI]).54 However, when including all trial
patients,52 a smaller reduction of these risks compared
with rivaroxaban has been shown (ie, HR of apixaban
versus rivaroxaban ¼ 0.90 [0.71–1.32]). Similarly,
differences in trial design, in which ARISTOTLE was
double-blinded and RE-LY was an open-label study,
may also be conservative favoring dabigatran, if
suggestions regarding the bias and overestimation of
treatment effects of open-label trials are valid.55–58
Although we acknowledge the limitations associ-
ated with the methods of adjustment used in the
indirect comparisons, we consider that these analysesFebruary 2014provide a reasonable comparison of treatment effects
and are of appropriate use in our model in the absence
of head-to-head trials. Furthermore, results generated
from this analysis are highly consistent with earlier
indirect comparisons,51–54 with minor deviations at-
tributed to use of odds ratios rather than HRs and use
of updated RE-LY6 data.
Overall, our predictions of the cost-effectiveness of
apixaban could be considered cautious, given that the
assumptions made in our study around input parameters
and the differences between our model and previous
models were likely to favor the comparator drugs.
CONCLUSIONS
The comprehensive assessment of the long-term efﬁ-
cacy, safety, and tolerability proﬁle of apixaban in this
study, generated through means of an economic
model, predicted that the drug would provide an
attractive alternative to other NOACs in the preven-
tion of thromboembolic events in patients with AF.
Speciﬁcally, it could offer favorable health beneﬁts for
a marginal increase in costs. In an economic environ-
ment of constrained health care resources, we believe
that the ﬁndings of this study may help UK payers in
making informed decisions that are in the best
interests of patients who have NVAF.
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Cost-Effectiveness of Apixaban Versus Other New
Oral Anticoagulants for Stroke Prevention in Patients
with Atrial Fibrillation: Indirect Comparison Analysis
(Using Event-Rate Data) to Assess Relative Efﬁcacy
and Safety of the New Oral Anticoagulants
OBJECTIVE
The following report details results of the indirect
comparison analysis conducted to examine the relative
efﬁcacy and safety of the new oral anticoagulants
(apixaban, dabigatran 110 mg, dabigatran 150 mg,
and rivaroxaban). This report is primarily focused on
reporting the hazard ratios (HRs) used as model inputs.
Analyses were conducted by using event-rate data
reported in the primary publications and related reports.
METHODS
The analysis is restricted to randomized controlled
trials of pharmacologic prophylaxis of stroke preven-
tion in patients with atrial ﬁbrillation.
Population
The population covered in the analysis included: (1)
patients with a risk of stroke and diagnosed with mild-
to-moderate nonvalvular atrial ﬁbrillation; and (2)
patients who were warfarin eligible.
Interventions for the Analysis
The following pharmacologic methods of prophy-
laxis were included: (1) apixaban; (2) rivaroxaban;
and (3) dabigatran etexilate.
Outcomes
Outcomes Reported
The current analysis analyzed event-rate data for
the following outcomes: ischemic or unspeciﬁed
stroke; myocardial infarction; intracranial hemor-
rhage; other major bleeds; clinically relevant non-
major (CRNM) bleed; and total discontinuations.
Studies Included in the Analyses
Three randomized controlled trials were included in
the analyses:1.FARISTOTLE (Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fi-
brillation)1: apixaban 5 mg BID versus warfarin;
international normalized ratio (INR), 2.0–3.0;ebruary 20142. ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) 2: rivaroxaban, 20 mg
once daily versus warfarin; INR, 2.0–3.0; and3. RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy)3: dabigatran, 110 mg
BID versus dabigatran 150 mg BID versus war-
farin; INR, 2.0–3.0.
Statistical Analysis
Direct and Indirect Meta-Analysis
Direct meta-analysis was conducted in Microsoft
Excel. The HRs and their SEs were calculated by using
standard formulae:
HR ¼ eventratea
eventrateb
¼ eventsa=PtTimeatRiska
eventsb=PtTimeatRiskb
SE½lnðHRÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=eventsaþ1=eventsb
p
Indirect comparisons between apixaban and other
treatments of interest via a common comparator were
made by using the method of Bucher et al4 and the
HRs produced from the direct meta-analysis. The
(indirect) HR between apixaban and the treatment
of interest is given by:
logðHRAVBÞ ¼ logðHRAVCÞ logðHRBVCÞ
with SE given by:
SE½ logðHRAVBÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE½ logðHRAVCÞ2
q
þSE½ logðHRBVCÞ2
For some studies, rates were estimated where the rate
events were not reported in the publication. The rates were
estimated from the number of patients experiencing an
outcome in cases in which the patient numbers were
reported but the rate of ﬁrst events was not reported. We
calculated the probability of experiencing an outcome at
the median follow-up point by dividing the number of ﬁrst
events by the number of patients randomized and con-
verted this probability into an annual rate as: rate = -ln(1-
probability)/median follow-up. This approximation accu-
rately predicted the event rate for studies in which both the
rate and number of patients with events were reported; this
value is particularly approximate for studies in which
patients were followed up for a ﬁxed period of time.
The analysis of event-rate outcomes was conducted
on an intent-to-treat (ITT) basis for efﬁcacy outcomes
and modiﬁed ITT (mITT) for safety outcomes. The
analysis was conducted for efﬁcacy end points in ITT210.e1
Clinical Therapeuticspopulations (or number randomized and received
treatment, if ITT ﬁgures are not reported). For adverse
events, the safety population used in the analysis was
the mITT population (number randomized and on
treatment, with ITT data used if mITT data not
reported). Similar analyses were performed for safety
outcomes: ITT as the ﬁrst analysis and per protocol as
the second analysis.
Connolly et al5 published an update to the original
RE-LY publication that reported several additional
primary efﬁcacy and safety outcome events noted
during routine clinical site closure visits after the
database was locked. “Data from the update of the
original RE-LY publication i.e. data reported in the
updated 2010 publication was used in the primary
analysis.”5 All the newly identiﬁed events were
adjudicated in a blinded fashion and in accordance
with the study protocol.
All efﬁcacy and safety analyses were reported on
the ITT population for RE-LY. In the present analysis,Supplemental Table I. Data used in analysis of ische
ROCKET-AF [Rivaroxaban Once
With Vitamin K Antagonism for
Fibrillation] publication) in warf
Study Treatment Arm
RE-LY
Dabigatran 110 mg BID
Warfarin; INR, 2.0–3.0
Dabigatran 150 mg BID
ROCKET-AF
Rivaroxaban 20 mg once daily
Warfarin, INR 2.0–3.0
ARISTOTLE
Apixaban 5 mg BID
Warfarin; INR, 2.0–3.0
RE-LY ¼ Randomized Evaluation of Long-Term Anticoagulation
¼ Apixaban for Reduction in Stroke and Other Thromboembol
*Intention-to-treat population (for ARISTOTLE, deﬁned as all
events from the time of randomization until the cutoff date fo
†Events occurring through the cutoff date (includes follow-up p
‡Reported in the publication as the intention-to-treat populatio
warfarin, n ¼ 7133). Patients excluded due to violations in Go
unreliable.
§Calculated event rates.
210.e2efﬁcacy results for ARISTOTLE are based on the ITT
population. For the ROCKET-AF study, apart from
primary efﬁcacy outcome (stroke or systemic embo-
lism), all secondary efﬁcacy outcomes were reported
on an on-treatment basis; although 14,264 patients
were randomized in the ROCKET-AF study, 93
patients (rivaroxaban, n = 50; warfarin, n = 43) were
excluded from all efﬁcacy analyses before unblinding
due to violations in Good Clinical Practice guidelines
at 1 site. Therefore, the denominators used in the
efﬁcacy analysis reported here are as follows: rivar-
oxaban, n = 7081; warfarin, n = 7090.
The safety analyses for ARISTOTLE were based on a
mITT population and included all patients who received
at least 1 dose of the study drug and included all events
from the time the ﬁrst dose of a study drug was received
until 2 days after the last dose was received. To align the
reporting of safety results from ROCKET-AF with those
from ARISTOTLE, the safety, as-treated population was
used for the denominator (all patients who received atmic þ unspecified stroke outcome (calculated for
Daily Oral Direct Factor Xa Inhibition Compared
Prevention of Stroke and Embolism Trial in Atrial
arin-eligible patients.
No. of Patients Event Rate (%/Year)
6015* 1.34†
6022* 1.21†
6076* 0.92†
7081‡ 1.15§
7090‡ 1.27§
9120* 0.97†
9081* 1.05†
Therapy; INR ¼ international normalized ratio; ARISTOTLE
ic Events in Atrial Fibrillation.
patients who underwent randomization and included all
r efﬁcacy outcomes).
eriod).
n (number of patients randomized: rivaroxaban, n ¼ 7131;
od Clinical Practice guidelines at 1 site that made the data
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events regardless of adherence to the protocol, while
they were receiving the assigned study drug or within 2
days after discontinuation).
Calculated events from dichotomous data were
used in cases in which event rates were not reported
in publications, and the calculated event-rate data
were used in the analyses for up to 2 decimal places
wherever possible.RESULTS
Indirect Comparison Analysis (Warfarin-Eligible
Patients)
The results reported in this section are based on the
groups of warfarin-eligible patients for indirect com-
parison analysis.Ischemicþ Unspecified Stroke (Calculated for ROCKET
Publication)
Data for RE-LY are that reported in the updated
2010 publication. Calculated HRs (95% [CIs]) for the
event ischemic or unspeciﬁed stroke are shown in
Supplemental Table I.
Supplemental Table II presents a comparison of
efﬁcacy between treatments for warfarin-eligible patients:
ischemic þ unspeciﬁed stroke (calculated for ROCKET
Publication).Supplemental Table II. Comparison of efficacy between
unspecified stroke (calculated fo
Factor Xa Inhibition Compared W
and Embolism Trial in Atrial Fib
Treatment
HR Versus Warfarin
(95% CI) Comparator
Apixaban 0.923 (0.746–1.143) Rivaroxaban
Dabigatran 110 mg
Dabigatran 150 mg
Rivaroxaban 0.905 (0.729–1.124) Dabigatran 110 mg
Dabigatran 150 mg
Dabigatran
110 mg BID
1.107 (0.883–1.388) Dabigatran 150 mg
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
February 2014Myocardial Infarction
Data for RE-LY are that reported in the updated
2010 publication. Calculated HRs (95% CIs) for the
event ischemic or unspeciﬁed stroke are shown in
Supplemental Table III. Supplemental Table IV
presets a comparison of efﬁcacy between treatments
for warfarin-eligible patients: myocardial infarction.Intracranial Hemorrhage
Data for RE-LY are that reported in the updated
2010 publication. Calculated HRs (95% CIs) for the
event ischemic or unspeciﬁed stroke are shown in
Supplemental Table V. Supplemental Table VI
presents a comparison of efﬁcacy between treatments
for warfarin-eligible patients: intracranial hemo-
rrhage.Other Major Bleeds (Major Bleeding Minus Intracranial
Hemorrhage: On-Treatment Analysis)
Data for RE-LY are that reported in the updated
2010 publication. Calculated HRs (95% CIs) for the
event ischemic or unspeciﬁed stroke are shown in
Supplemental Table VII. Supplemental Table VIII
presents a comparison of efﬁcacy between treatments
for warfarin-eligible patients: other major bleeds
(calculated event rates).treatments for warfarin-eligible patients: ischemic þ
r ROCKET-AF [Rivaroxaban Once Daily Oral Direct
ith Vitamin K Antagonism for Prevention of Stroke
rillation] publication).*
HR Versus Warfarin
(95% CI)
Indirect Comparison:
Comparator Versus
Treatment HR (95% CI)
0.905 (0.729–1.124) 0.980 (0.723–1.328)
BD 1.107 (0.883–1.388) 1.198 (0.878–1.635)
BD 0.760 (0.593–0.974) 0.823 (0.593–1.141)
BD 1.107 (0.883–1.388) 1.222 (0.894–1.672)
BD 0.760 (0.593–0.974) 0.839 (0.604–1.167)
BID 0.760 (0.593–0.974) 0.686 (0.490–0.960)
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Supplemental Table III. Data used in analysis of myocardial infarction outcome in warfarin-eligible patients.
Study Treatment Arm No. of Patients Event Rate (%/Year)
RE-LY
Dabigatran 110 mg BID 6015* 0.82†
Warfarin; INR, 2.0–3.0 6022* 0.64†
Dabigatran 150 mg BID 6076* 0.81†
ROCKET-AF
Rivaroxaban 20 mg once daily 7081‡ 0.91§
Warfarin; INR, 2.0–3.0 7090‡ 1.12§
ARISTOTLE
Apixaban 5 mg BID 9120* 0.53†
Warfarin; INR, 2.0–3.0 9081* 0.61†
RE-LY ¼ Randomized Evaluation of Long-Term Anticoagulation Therapy; INR ¼ international normalized ratio; ROCKET-AF
¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation.
*Intention-to-treat population (for ARISTOTLE, deﬁned as all patients who underwent randomization and included all
events from the time of randomization until the cutoff date for efﬁcacy outcomes).
†Events occurring through the cutoff date (includes follow-up period).
‡Reported in the publication as the intention-to-treat population (number of patients randomized: rivaroxaban, n ¼ 7131;
warfarin, n ¼ 7133). Patients excluded due to violations in Good Clinical Practice guidelines at 1 site that made the data
unreliable.
§Safety-on-treatment population, including patients who received Z1 dose of study drug and were followed up for events,
regardless of adherence to the protocol, while they were receiving the assigned study drug or within 2 days after
discontinuation.
Supplemental Table IV. Comparison of efficacy between treatments for warfarin-eligible patients: myocardial
infarction.*
Treatment
HR Versus Warfarin
(95% CI) Comparator
HR Versus Warfarin
(95% CI)
Indirect Comparison: Comparator
Versus Treatment HR (95% CI)
Apixaban 0.868 (0.654–1.153) Rivaroxaban 0.812 (0.625–1.055) 0.935 (0.635–1.375)
Dabigatran 110 mg BiD 1.281 (0.925–1.773) 1.474 (0.958–2.269)
Dabigatran 150 mg BiD 1.265 (0.916–1.747) 1.456 (0.948–2.238)
Rivaroxaban 0.812 (0.625–1.055) Dabigatran 110 mg BiD 1.281 (0.925–1.773) 1.576 (1.038–2.393)
Dabigatran 150 mg BiD 1.265 (0.916–1.747) 1.557 (1.028–2.360)
Dabigatran 110 mg BID 1.281 (0.925–1.773) Dabigatran 150 mg BiD 1.265 (0.916–1.747) 0.987 (0.624–1.561)
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
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Supplemental Table V. Data used in analysis of intracranial hemorrhage in warfarin-eligible patients.
Study Treatment Arm No. of Patients Event Rate (%/Year)
RE-LY
Dabigatran 110 mg BID 6015* 0.23†
Warfarin; INR, 2.0–3.0 6022* 0.76†
Dabigatran 150 mg BID 6076* 0.32†
ROCKET-AF
Rivaroxaban 20 mg OD 7061‡ 0.5§
Warfarin; INR, 2.0–3.0 7082‡ 0.7§
ARISTOTLE
Apixaban 5 mg BID 9088ǁ 0.33§
Warfarin; INR, 2.0–3.0 9052ǁ 0.8§
RE-LY ¼ Randomized Evaluation of Long-Term Anticoagulation Therapy; INR ¼ international normalized ratio; ROCKET-AF ¼
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation.
*Intention-to-treat population.
†Events occurring through the cutoff date (includes follow-up period).
‡Patients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol,
while they were receiving the drug or within 2 days after discontinuation.
§Events occurring during the treatment period or within 2 days after discontinuation (excluding follow-up).
ǁPatients who received at least 1 dose of study drug and events that occurred from the time the patients received the ﬁrst dose
of the study drug through 2 days after they received the last dose.
Supplemental Table VI. Comparison of efficacy between treatments for warfarin-eligible patients: intracranial
hemorrhage.*
Treatment
HR Versus Warfarin
(95% CI) Comparator
HR Versus Warfarin
(95% CI)
Indirect Comparison: Comparator
Versus Treatment HR (95% CI)
Apixaban 0.412 (0.298–0.570) Rivaroxaban 0.714 (0.508–1.003) 1.731 (1.082–2.770)
Dabigatran 110 mg BID 0.302 (0.196–0.465) 0.733 (0.428–1.257)
Dabigatran 150 mg BID 0.421 (0.288–0.615) 1.020 (0.619–1.681)
Rivaroxaban 0.714 (0.508–1.003) Dabigatran 110 mg BID 0.302 (0.196–0.465) 0.423 (0.244–0.733)
Dabigatran 150 mg BID 0.421 (0.288–0.615) 0.589 (0.354–0.980)
Dabigatran 110 mg BID 0.302 (0.196–0.465) Dabigatran 150 mg BID 0.421 (0.288–0.615) 1.391 (0.784–2.468)
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
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Supplemental Table VII. Data used in analysis of other major bleeds (calculated event rates) in warfarin-
eligible patients.
Study Treatment Arm No. of Patients Event Rate (%/Year)
RE-LY
Dabigatran 110 mg BID 6015* 2.69†
Warfarin; INR, 2.0–3.0 6022* 2.83†
Dabigatran 150 mg BID 6076* 3.06†
ROCKET-AF
Rivaroxaban 20 mg once daily 7061‡ 3.07§
Warfarin; INR, 2.0–3.0 7082‡ 2.71§
ARISTOTLE
Apixaban 5 mg BID 9088ǁ 1.79
Warfarin; INR, 2.0–3.0 9052ǁ 2.27
RE-LY ¼ Randomized Evaluation of Long-Term Anticoagulation Therapy; INR ¼ international normalized ratio; ROCKET-AF
¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation.
*Intention-to-treat numbers, randomized.
†Calculated event rates.
‡Patients who received at least 1 dose of study drug and events that occurred from the time the patients received the ﬁrst
dose of the study drug through 2 days after they received the last dose.
§Calculated event rates with median on-treatment follow-up.
ǁPatients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol,
while they were receiving the drug or within 2 days after discontinuation.
Clinical TherapeuticsCRNM Bleed (ARISTOTLE Clinical Study Report
Data) (Including Minor Bleed as Reported in RE-LY
for Dabigatran)
Calculated HRs (95% CIs) for the event ischemic
or unspeciﬁed stroke are shown in Supplemental
Table IX. Supplemental Table X presents a
comparison of efﬁcacy between treatments forSupplemental Table VIII. Comparison of efficacy betw
major bleeds (calculated even
Treatment
HR Versus Warfarin
(95% CI) Comparator
Apixaban 0.788 (0.672–0.924) Rivaroxaban
Dabigatran 110 mg
Dabigatran 150 mg
Rivaroxaban 1.132 (0.970–1.322) Dabigatran 110 mg
Dabigatran 150 mg
Dabigatran 110 mg BID 0.950 (0.814–1.109) Dabigatran 150 mg
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
210.e6warfarin-eligible patients: CRNM bleed (minor bleed
data used for RE-LY).
Total Discontinuations (Calculated Event Rates)
Calculated HRs (95% CIs) for the event ischemic or
unspeciﬁed stroke are shown in Supplemental Table
XI. Supplemental Table XII presents a comparison ofeen treatments for warfarin-eligible patients: other
t rates).*
HR Versus Warfarin
(95% CI)
Indirect Comparison: Comparator
Versus Treatment HR (95% CI)
1.132 (0.970–1.322) 1.436 (1.150–1.793)
BID 0.950 (0.814–1.109) 1.205 (0.965–1.504)
BID 1.081 (0.931–1.255) 1.371 (1.102–1.705)
BID 0.950 (0.814–1.109) 0.839 (0.674–1.044)
BID 1.081 (0.931–1.255) 0.954 (0.769–1.183)
BID 1.081 (0.931–1.255) 1.137 (0.917–1.409)
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Supplemental Table IX. Data used in analysis of clinically relevant nonmajor bleed (minor bleed data used for
RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy]) in warfarin-
eligible patients.
Study Treatment Arm No. of Patients Event Rate (%/Year)
RE-LY minor bleed*
Dabigatran 110 mg BID 6015† 13.16‡
Warfarin; INR, 2.0–3.0 6022† 16.37‡
Dabigatran 150 mg BID 6076† 14.84‡
ROCKET-AF
Rivaroxaban 20 mg once daily 7061§ 11.8ǁ
Warfarin; INR, 2.0–3.0 7082§ 11.4ǁ
ARISTOTLE
Apixaban 5 mg BID 9088¶ 2.083ǁ
Warfarin; INR, 2.0–3.0 9052¶ 2.995ǁ
INR ¼ international normalized ratio; ROCKET-AF ¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared
With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE ¼ Apixaban for
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.
*Deﬁned as all bleeds that did not meet the deﬁnition of major bleed or clinically relevant nonmajor bleed.
†Intention-to-treat population.
‡Events occurring through the cutoff date (includes follow-up period).
§Patients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol,
while they were receiving the drug or within 2 days after discontinuation.
ǁEvents during the treatment period or within 2 days after discontinuation (as reported in the clinical study report).
¶Patients who received at least 1 dose of study drug and events that occurred from the time the patients received the ﬁrst
dose of the study drug through 2 days after they received the last dose.
Supplemental Table X. Comparison of efficacy between treatments for warfarin-eligible patients: clinically
relevant nonmajor bleed (minor bleed data used for RE-LY LY [Randomized
Evaluation of Long-Term Anticoagulation Therapy]).*
Treatment HR Versus Warfarin (95% CI) Comparator HR Versus Warfarin (95% CI)
Apixaban 0.695 (0.602–0.803) Rivaroxaban 1.035 (0.954–1.122)
Dabigatran 110 mg BID 0.803 (0.752–0.859)
Dabigatran 150 mg BID 0.906 (0.850–0.966)
Rivaroxaban 1.035 (0.954–1.122) Dabigatran 110 mg BID 0.803 (0.752–0.859)
Dabigatran 150 mg BID 0.906 (0.850–0.966)
Dabigatran 110 mg BD 0.803 (0.752–0.859) Dabigatran 150 mg BID 0.906 (0.850–0.966)
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
G.Y.H. Lip et al.
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Table XI. Data used in analysis of total discontinuations outcome (calculated event rates) in warfarin-eligible
patients.
Study Treatment Arm No. of Patients Event Rate (%/Year)
RE-LY*
Dabigatran 110 mg BID 6015† 10.72‡§
Warfarin; INR, 2.0–3.0 6022† 8.11‡§
Dabigatran 150 mg BID 6076† 11.11‡§
ROCKET-AFǁ
Rivaroxaban 20 mg once daily 7131¶ 14.02‡#
Warfarin, INR 2.0–3.0 7133¶ 13.01‡#
ARISTOTLE**
Apixaban 5 mg BID 9120† 16.23‡††
Warfarin; INR, 2.0–3.0 9081† 17.83‡††
RE-LY ¼ Randomized Evaluation of Long-Term Anticoagulation Therapy; INR ¼ international normalized ratio; ROCKET-AF
¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation; ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation.
*Median follow-up is 2 years.
†Randomized numbers.
‡Calculated event rates from the dichotomous data.
§Number of patients who discontinued at 2 years.
ǁMedian follow-up is 707 days or 1.93 years.
¶Number of patients randomized: rivaroxaban, n ¼ 7131; warfarin, n ¼ 7133.
#Patients lost to follow-up, experiencing primary end point, death, Good clinical practice violating site/closed site patients,
and those not receiving any study drug excluded.
**Median follow-up is 1.8 years.
††Accounted for “end of treatment period” randomized patients (as reported in the clinical study report).
Supplemental Table XII. Comparison of efficacy between treatments for warfarin-eligible patients: total
discontinuations (calculated event rates).*
Treatment
HR Versus Warfarin
(95% CI) Comparator
HR Versus Warfarin
(95% CI)
Indirect Comparison: Comparator
Versus Treatment HR (95% CI)
Apixaban 0.910 (0.860–0.963) Rivaroxaban 1.077 (1.006–1.154) 1.184 (1.083–1.294)
Dabigatran 110 mg BID 1.321 (1.211–1.441) 1.452 (1.309–1.611)
Dabigatran 150 mg BID 1.369 (1.256–1.493) 1.505 (1.357–1.668)
Rivaroxaban 1.077 (1.006–1.154) Dabigatran 110 mg BID 1.321 (1.211–1.441) 1.226 (1.097–1.369)
Dabigatran 150 mg BID 1.369 (1.256–1.493) 1.270 (1.138–1.418)
Dabigatran 110 mg BID 1.321 (1.211–1.441) Dabigatran 150 mg BID 1.369 (1.256–1.493) 1.036 (0.917–1.171)
HR ¼ hazard ratio.
*Signiﬁcant differences are shown in bold.
Clinical Therapeutics
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G.Y.H. Lip et al.efﬁcacy between treatments for warfarin-eligible pa-
tients: total discontinuations (calculated event rates).
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Clinical TherapeuticsSUPPLEMENTAL APPENDIX B
Cost-Effectiveness of Apixaban versus Other New
Oral Anticoagulants for Stroke Prevention in Patients
with Atrial Fibrillation: Secondary Analysis of ARIS-
TOTLE (CV185-030) to Support Apixaban Cost
Effectiveness Modelling for the Indication of Stroke
Prevention in Atrial FibrillationSTUDY DESIGN
Study design and data collection associated with
ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation)
have been described previously.1 Seminal results,
published by Granger et al,2 indicated that apixaban
was superior to warfarin in terms of prevention of
stroke and systemic embolism, reduction in major
bleeding, and reduction in all-cause mortality.METHODS
ARISTOTLE data were analyzed on a post hoc basis.
Annualized event rates and related hazard ratios were
computed for the relevant end points. The intention-
to-treat (ITT) principle was used for the analysis of all
end points except the safety end points (which were
based on the modiﬁed ITT population). Stratiﬁed
analyses were conducted across CHADS2 (congestive
heart failure, hypertension, age Z75 years, diabetes
mellitus, prior stroke or transient ischemic attack, or
thromboembolism) categories.3 All risks were assessed
in absolute terms or relative risk was computed by
using hazard ratios for the event associated with
warfarin versus apixaban. Drug-speciﬁc (ie, separately
for apixaban as well as for warfarin) analysis of the
center’s time in therapeutic range (cTTR) was con-
ducted by estimating the relative hazard of experienc-
ing an event in a cTTR quartile versus that observed in
the reference cTTR quartile of 52.38% r cTTR
o66.02%.4 This quartile was chosen as a reference
quartile because it encompassed the median TTR
of 66%.
Mortality risk associated with reasons other than
stroke, systemic embolism, bleeding, and myocardial
infarction was assessed by deleting mortality associ-
ated with the aforementioned causes from all-cause
mortality. Absolute mortality risk as well as relative
hazard of mortality with warfarin versus apixaban for
causes other than stroke, bleeding, and myocardial
infarction was assessed.210.e10Data were pooled from the treatment arms of
ARISTOTLE and AVERROES (Apixaban Versus Ace-
tylsalicylic Acid to Prevent Strokes) to assess fatality
rates associated with intracranial hemorrhages, ex-
cluding hemorrhagic stroke and other major bleeds
excluding any type of intracranial hemorrhages.
All analyses were conducted by using SAS version
9.2 (SAS Institute, Inc, Cary, North Carolina). Be-
cause this was a secondary analysis of ARISTOTLE
analyses sets performed in a post hoc manner, no
statistical signiﬁcance was assessed.
Risk of an Event by cTTR Quartiles
Ischemic and Unspecified Stroke
cTTR quartiles (as described in the ARISTOTLE
clinical study report Table 7.1.1.4) were used for
the purpose of this analysis.4 Supplemental Table I
describes the risk of ischemic or unspeciﬁed stroke
according to cTTR quartiles associated with
apixaban. Supplemental Table II describes the risk
of ischemic or unspeciﬁed stroke according to cTTR
quartiles associated with warfarin.
Intracranial Hemorrhages
Similar to ischemic or unspeciﬁed stroke, risk of
intracranial hemorrhages was assessed across cTTR
quartiles, as described earlier. 4 Supplemental Tables
III and IV describe the event rate and relative hazard
ratios (HRs) for intracranial hemorrhage associated
with apixaban and warfarin, respectively.
Other Major Bleeds Excluding Intracranial
Hemorrhages
Other major bleeds were deﬁned as major bleeds
excluding intracranial hemorrhages. Supplemental
Tables V and VI describe the event rate and relative
HRs for other major bleeds associated with apixaban
and warfarin, respectively.
Clinically Relevant Nonmajor Bleeding
Event rates and associated HRs associated with
clinically relevant nonmajor bleeding are described in
Supplemental Tables VII and VIII for apixaban and
warfarin, respectively.
Risk of Ischemic or Unspecified Stroke by
CHADS2 Score
Risk of ischemic or unspeciﬁed stroke was assessed
at prespeciﬁed CHADS2 categories of 0 to 1, 2, andVolume 36 Number 2
Supplemental Table II. Ischemic or unspecified stroke risk according to center’s time in therapeutic range
(cTTR) quartiles for warfarin.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 34 1.678 1.542 (1.022–2.328)
52.38% r cTTR o66.02% 68 1.078 1.000 (Ref.)
66.02% r cTTR o76.51% 58 0.912 0.836 (0.588–1.188)
cTTR Z76.51% 15 0.778 0.717 (0.410–1.254)
HR ¼ hazard ratio.
Supplemental Table III. Intracranial hemorrhage risk by center’s time in therapeutic range (cTTR) quartiles for
apixaban.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 5 0.259 0.581 (0.223–1.514)
52.38% r cTTR o 66.02% 26 0.447 1.000 (Ref.)
66.02% r cTTR o 76.51% 18 0.307 0.688 (0.377–1.256)
cTTR Z76.51% 3 0.161 0.361 (0.109–1.194)
HR ¼ hazard ratio.
Supplemental Table I. Ischemic or unspecified stroke risk according to center’s time in therapeutic range
(cTTR) quartiles for apixaban.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 23 1.091 0.922 (0.578–1.472)
52.38% r cTTR o66.02% 74 1.178 1.000 (Ref.)
66.02% r cTTR o76.51% 51 0.806 0.690 (0.483–0.986)
cTTR Z76.51% 13 0.656 0.561 (0.311–1.011)
HR ¼ hazard ratio.
G.Y.H. Lip et al.Z3 as speciﬁed in the seminal ARISTOTLE publica-
tion. As demonstrated in Supplemental Table IX, this
risk was assessed separately for each treatment arm.
Weighted average risk of ischemic or unspeciﬁedFebruary 2014stroke was 0.981 and 1.077 for apixaban and
warfarin, respectively, with weights computed based
on number of patients in different CHADS2 categories
for each treatment arm within ARISTOTLE.210.e11
Supplemental Table IV. Intracranial hemorrhage risk according to center’s time in therapeutic range (cTTR)
quartiles for warfarin.
Stroke No. Event Rate HR (95% CI)
cTTRo52.38% 18 0.997 1.052 (0.617–1.793)
52.38% r cTTR o66.02% 54 0.941 1.000 (Ref.)
66.02% r cTTR o76.51% 37 0.633 0.681 (0.448–1.034)
cTTR Z76.51% 15 0.721 0.777 (0.424–1.424)
HR ¼ hazard ratio.
Supplemental Table V. Other major bleeding risk according to center’s time in therapeutic range (cTTR)
quartiles for apixaban.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 19 0.991 0.722 (0.438–1.191)
52.38% r cTTR o 66.02% 79 1.369 1.000 (Ref.)
66.02% r cTTR o 76.51% 132 2.297 1.688 (1.277–2.231)
cTTR Z76.51% 44 2.402 1.765 (1.221–2.552)
HR ¼ hazard ratio.
Supplemental Table VI. Other major bleeding risk according to center’s time in therapeutic range (cTTR)
quartiles for warfarin.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 32 1.796 0.843 (0.571–1.245)
52.38% r cTTR o66.02% 120 2.120 1.000 (Ref.)
66.02% r cTTR o76.51% 137 2.383 1.130 (0.884–1.443)
cTTR Z76.51% 51 2.876 1.365 (0.984–1.895)
HR ¼ hazard ratio.
Clinical Therapeutics
210.e12 Volume 36 Number 2
Supplemental Table VIII. Clinically relevant nonmajor bleeding risk according to center’s time in therapeutic
range (cTTR) quartiles for warfarin.
Stroke No. Event Rate HR (95% CI)
cTTR o 52.38% 47 2.659 0.987 (0.711–1.369)
52.38% r cTTR o66.02% 150 2.667 1.000 (Ref.)
66.02% r cTTR o76.51% 189 3.316 1.256 (1.014–1.556)
cTTR Z76.51% 58 3.341 1.266 (0.935–1.714)
HR ¼ hazard ratio.
Supplemental Table VII. Clinically relevant nonmajor bleeding risk according to center’s time in therapeutic
range (cTTR) quartiles for apixaban.
Stroke No. Event Rate HR (95% CI)
cTTR o52.38% 25 1.307 0.711 (0.460–1.100)
52.38% r cTTR o66.02% 105 1.829 1.000 (Ref.)
66.02% r cTTR o76.51% 130 2.265 1.247 (0.964–1.613)
cTTR Z76.51% 56 3.094 1.702 (1.230–2.354)
HR ¼ hazard ratio.
Supplemental Table IX. Ischemic or unspecified stroke risk according to CHADS2 (congestive heart failure,
hypertension, age Z75 years, diabetes mellitus, prior stroke or transient ischemic
attack, or thromboembolism) score.
CHADS2 Score Apixaban Warfarin
0–1 0.521 0.458
2 0.950 0.934
Z3 1.534 1.944
Weighted average 0.981 1.077
G.Y.H. Lip et al.AVERAGE RISK ASSOCIATED WITH
BLEEDING EVENTS
The average risk of events, as described in
Supplemental Table X, was observed in patients
using apixaban versus warfarin in ARISTOTLE
patients.Hemorrhagic Stroke as a Part of Intracranial
Hemorrhages
Hemorrhagic strokes comprised 77% of intracranial
hemorrhages observed in apixaban-treated patientsFebruary 2014(40 of 52) versus 64% of intracranial hemorrhages
observed in warfarin-treated patients (78 of 122). As
stated earlier, the absolute event risk of experiencing
intracranial hemorrhages was higher with warfarin
versus apixaban.Severity Distribution Associated with Strokes as
Assessed by Modified Rankin Score
The distribution of stroke severity was
observed by using modiﬁed Rankin Scale scores
at 30-day follow-up postevent for apixaban210.e13
Supplemental Table X. Average risk of bleeding events as observed in ARISTOTLE (Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial Fibrillation) in apixaban and
warfarin arms.
Event
Apixaban
(per 100 Patient-Years)
Warfarin
(per 100 Patient-Years)
Intracranial hemorrhage 0.330 0.800
Other major bleeds excluding intracranial hemorrhages 1.790 2.270
Clinically relevant nonmajor bleeding 2.083 2.995
Supplemental Table XI. Stroke severity classification associated with ischemic or unspecified stroke.* Values
are given as number (%).
mRS classiﬁcation Apixaban Warfarin
0–2 57 (53) 49 (45)
3–4 23 (21) 32 (30)
5 9 (8) 11 (10)
6 19 (18) 16 (15)
*Information about modiﬁed Rankin Scale (mRS) classiﬁcation was not available for 54 ischemic or unspeciﬁed stroke
events in the apixaban arm and 67 ischemic or unspeciﬁed events in the warfarin arm of ARISTOTLE (Apixaban for
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Supplemental Table XII. Stroke severity classification associated with hemorrhagic stroke.* Values are given as
number (%).
mRS Classiﬁcation Apixaban Warfarin
0–2 7 (23%) 13 (20%)
3–4 10 (32%) 10 (15%)
5 3 (10%) 8 (12%)
6 11 (35%) 34 (53%)
*Information about modiﬁed Rankin Scale (mRS) classiﬁcation was not available for 9 hemorrhagic stroke events in the
apixaban arm and 13 hemorrhagic stroke events in the warfarin arm of ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation).
Clinical Therapeutics(Supplemental Table XI) versus warfarin
(Supplemental Table XII). Patients with a modiﬁed
Rankin Scale score of 6 represented fatality associated
with the stroke event.210.e14Ischemic or Unspecified Stroke
Supplemental Table XI presents the stroke severity
classiﬁcation associated with ischemic or unspeciﬁed
stroke.Volume 36 Number 2
Supplemental Table XIV. Pooled analysis of fatality rates associated with apixaban versus warfarin or aspirin
using ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) and AVERROES (Apixaban Versus Acetylsalicylic Acid to
Prevent Strokes) data.
Trial Treatment Other ICH Fatal Other ICH OMB Fatal OMB
AVERROES Apixaban 5 1 (20%) 34 1 (3%)
Aspirin 2 1 (50%) 18 1 (6%)
ARISTOTLE Apixaban 12 2 (17%) 275 6 (2%)
Warfarin 44 4 (9%) 340 7 (2%)
Overall average 63 8 (13%) 667 15 (2%)
ICH ¼ intracranial hemorrhage; OMB ¼ other major bleed.
Supplemental Table XIII. Treatment discontinuation rates not related to absorbing states.*
Treatment No. Event Rate HR (95% CI)
Warfarin 2182 14.405 1.089 (1.025–1.157)
Apixaban 2047 13.177 1.000 (Ref.)
HR ¼ hazard ratio.
*Excluding stroke, major bleeding, myocardial infarction, or systemic embolism.
G.Y.H. Lip et al.Hemorrhagic Stroke
Supplemental Table XII presents the stroke severity
classiﬁcation associated with hemorrhagic stroke.
Treatment Discontinuation Rates Not Related
to Absorbing States
Treatment discontinuation rates for reasons other
than stroke or major bleeding were higher for war-
farin versus those observed for apixaban. This re-
sulted in greater HRs for warfarin versus apixaban
both for treatment discontinuations related to: (1)
excluding stroke or major bleeding; and (2) excluding
stroke, major bleeding, myocardial infarction, or
systemic embolism (Supplemental Table XIII).
Fatality Rates Associated with Bleeding Episodes
Pooled data analyses, as described in Supplemental
Table XIV, indicated 13% mortality associated with
intracranial hemorrhage that did not manifest into
hemorrhagic stroke. Pooled mortality rate for otherFebruary 2014major bleeds that were not intracranial in nature
was 2%.
Mortality Risk Associated With Causes Other
Than Stroke, Systemic Embolism, Major
Bleeding, or Myocardial Infarction
Over the duration of the ARISTOTLE trial, apix-
aban had a nonstroke, non–systemic embolism, non-
bleeding, and nonmyocardial infarction mortality rate
of 3.0825 per 100 patient-years (n ¼ 528) versus
warfarin, which had mortality rate of 3.3404 per 100
patient-years (n ¼ 568). The resulting hazard ratio
was 1.0836 (95% CI, 0.962–1.220).
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Cost-Effectiveness of Apixaban Versus Other New
Oral Anticoagulants for Stroke Prevention in Patients
with Atrial Fibrillation: Secondary Analysis of AVER-
ROES (CV185-048) to Support Apixaban Cost-
Effectiveness Modelling for the Indication of Stroke
Prevention in Atrial Fibrillation
STUDY DESIGN
Study design and data collection associated with the
AVERROES (ApixabanVersus Acetylsalicylic Acid to
Prevent Strokes) trial have been described previously.1
Seminal results, published by Connolly et al,2 indi-
cated that apixaban reduced the risk of stroke or
systemic embolism without signiﬁcantly increasing the
risk of major bleeding or intracranial hemorrhage.
METHODS
AVERROES data were analyzed on a post hoc basis.
Annualized event rates and related hazard ratios
(HRs) were computed for the relevant end points.
The intention-to-treat (ITT) principle was used for the
analysis of all end points except the safety end points
(which were based on the modiﬁed ITT population).
Stratiﬁed analyses were conducted across CHADS2
(congestive heart failure, hypertension, age Z75
years, diabetes mellitus, prior stroke or transient
ischemic attack, or thromboembolism) categories.3
All risks were assessed in absolute terms or relative
risk was computed by using HRs for the events
associated with aspirin versus apixaban. Subgroup
analyses were conducted in AVERROES participants
who had previously used warfarin (vitamin K
antagonists [VKAs]) but were not able to stay on the
VKA due to their inability to maintain international
normalized ratio control while on warfarin, because
they experienced either bleeding or nonbleeding events
while on warfarin, or for other similar reasons
described in the AVERROES publication.2 For the
purposes of these analyses, the patients were labeled
as the warfarin-unsuitable population (ie, proven
unsuitable after experiencing warfarin use).
Mortality risk associated with reasons other than
stroke, systemic embolism, bleeding, and myocardial
infarction was assessed by deleting mortality associ-
ated with the aforementioned causes from all-cause
mortality. Absolute mortality risk as well as relative
hazard of mortality with aspirin versus apixaban for
causes other than stroke, bleeding, and myocardialFebruary 2014infarction was assessed. Apixaban was used as a
reference category for computing HRs associated with
these events.
Data were pooled from ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) and AVERROES treat-
ment arms to assess percentage of intracranial hem-
orrhages manifesting into hemorrhagic stroke, as well
as fatality rates associated with intracranial hemor-
rhages (excluding hemorrhagic stroke and other major
bleeds [excluding any type of intracranial hemor-
rhage]). For assessing distribution of hemorrhagic
stroke across different levels of stroke severity, events
were pooled across the apixaban and aspirin arms due
to low absolute event rates in both arms.
All analyses were conducted by using SAS version
9.2 (SAS Institute, Inc, Cary, North Carolina). Be-
cause this was a secondary analysis of AVERROES
analyses sets conducted in a post hoc manner, please
refer to the article by Connolly et al for efﬁcacy and
safety results obtained based on prespeciﬁed primary
and secondary hypotheses.
Risk of Ischemic or Unspecified Stroke According
to CHADS2 Score
Risk of ischemic or unspeciﬁed stroke was assessed
at prespeciﬁed CHADS2 categories of 0 to 1, 2, and
Z3, as speciﬁed in the AVERROES publication.2 As
demonstrated in Supplemental Table I, this risk was
assessed separately for each treatment arm. Weighted
average risk of ischemic or unspeciﬁed stroke was
1.374 and 3.103 for apixaban and aspirin, res-
pectively, with weights computed based on number
of patients in different CHADS2 categories for each
treatment arm within AVERROES. Compared with
apixaban, patients treated with aspirin had a greater
risk of experiencing ischemic or unspeciﬁed stroke (HR
¼ 2.270 [95% CI, 1.590–3.230]).
Risk of Experiencing Bleeding or Other Events
Supplemental Table II describes the absolute event
rates (per 100 patient-years) and relative risk (as HRs)
of experiencing an event when treated with aspirin
versus apixaban.
Hemorrhagic Stroke as a Part of Intracranial
Hemorrhages
Hemorrhagic strokes comprised 55% of intracra-
nial hemorrhages observed in patients treated with210.e17
Supplemental Table I. Ischemic or unspecified stroke risk according to CHADS2 (congestive heart failure,
hypertension, age Z75 years, diabetes mellitus, prior stroke or transient ischemic
attack, or thromboembolism) score.
CHADS2 Score Apixaban Aspirin
0–1 0.831 1.411
2 1.526 3.363
Z3 1.957 5.196
Weighted average 1.374 3.103
Supplemental Table II. Absolute and relative hazard of experiencing an event with apixaban versus aspirin in
the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) trial
population.
Event
Apixaban Absolute
Event Rate
Aspirin Absolute
Event Rate
Hazard Ratio
(95% CI)
Intracranial hemorrhages 0.344 0.348 1.013 (0.439–2.337)
Other major bleeds excluding intracranial
hemorrhages
1.066 0.571 0.535 (0.302–0.947)
Clinically relevant nonmajor bleeding 3.113 2.371 0.762 (0.563–1.030)
CV hospitalizations unrelated to stroke or MI 10.460 12.087 1.155 (0.992–1.345)
CV ¼ cardiovascular; MI ¼ myocardial infarction.
Clinical Therapeuticsapixaban and aspirin. As described in the AVERROES
publication,2 patients taking apixaban had slightly
lower risk of experiencing intracranial hemorrhages
(HR ¼ 0.85 [0.38–1.90]) well as hemorrhagic stroke
(HR ¼ 0.37 [0.24–1.88]) compared with patients
taking aspirin.
Severity Distribution Associated With Strokes as
Assessed by Modified Rankin Scale
The distribution of stroke severity was observed
by using the modiﬁed Rankin Scale at 30-day follow-
up postevent for apixaban versus aspirin. Patients
with a modiﬁed Rankin Scale score of 6 represented
fatality associated with the stroke event. Stroke
severity distribution associated with ischemic or un-
speciﬁed stroke according to treatment is described in
Supplemental Table III. For hemorrhagic stroke,
events were pooled across the apixaban and aspirin210.e18arms due to low absolute event rate in both arms for
this analysis (Supplemental Table IV).
Gastrointestinal Bleeding Rates as Part of Other
Major Bleeding (Excluding Intracranial
Hemorrhages)
Gastrointestinal bleeding comprised 35% (12 of
34) and 39% (7 of 18) of other major bleeding events
(excluding intracranial hemorrhages) for apixaban
and aspirin, respectively.
Treatment Discontinuation Rates Not Related
to Absorbing States
Treatment discontinuation rate for reasons other
than stroke or major bleeding were higher for
aspirin versus that observed for apixaban, resul-
ting into greater HRs for aspirin versus apixaban
for treatment discontinuations not related to: (1)Volume 36 Number 2
Supplemental Table III. Stroke severity classification associated with ischemic or unspecified stroke. Values
are given as number (%).
mRS Classiﬁcation Apixaban Aspirin
0–2 17 (40) 35 (36)
3–4 12 (28) 37 (38)
5 5 (12) 15 (15)
6 9 (20) 10 (11)
mRS ¼ modiﬁed Rankin Scale.
Supplemental Table IV. Stroke severity classification associated with hemorrhagic stroke.
mRS
Classiﬁcation
Apixaban
(No.)
Aspirin
(No.)
Pooled Sample
(No. [%])
0–2 1 0 1 (7)
3–4 1 2 3 (20)
5 0 4 4 (27)
6 4 3 7 (46)
mRS ¼ modiﬁed Rankin Scale.
Supplemental Table V. Treatment discontinuation rates not related to absorbing states.*
Drug No. Event Rate (per 100 Patient Years) Hazard Ratio (95% CI)
Aspirin 537 19.012 1.099 (0.972–1.241)
Apixaban 495 17.310 1.000 (Ref.)
*Excluding stroke, major bleeding, myocardial infarction, and systemic embolism.
G.Y.H. Lip et al.stroke or major bleeding; or (2) stroke, major bleed-
ing, myocardial infarction, or systemic embolism
(Supplemental Table V).
Fatality Rates Associated With Bleeding Episodes
Pooled data analyses, as described in Supplemental
Table VI, indicated 13% mortality associated with
intracranial hemorrhage that did not manifest intoFebruary 2014hemorrhagic stroke. The pooled morality rate for other
major bleeds that were not intracranial in nature was 2%.
Mortality Risk Associated With Causes Other
Than Stroke, Systemic Embolism, Major
Bleeding, or Myocardial Infarction
Over the duration of the AVERROES trial, the
aspirin arm exhibited higher nonstroke, nonsystemic210.e19
Supplemental Table VI. Pooled analysis of fatality rates associated with apixaban Supplemental versus
warfarin or aspirin by using the ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) and AVERROES (Apixaban
Versus Acetylsalicylic Acid to Prevent Strokes) data.
Trial Treatment Other ICH Fatal Other ICH OMB Fatal OMB
AVERROES Apixaban 5 1 (20%) 34 1 (3%)
Aspirin 2 1 (50%) 18 1 (6%)
ARISTOTLE Apixaban 12 2 (17%) 275 6 (2%)
Warfarin 44 4 (9%) 340 7 (25)
Average 63 8 (13%) 667 15 (2%)
ICH ¼ intracranial hemorrhages; OMB ¼ other major bleeds.
Supplemental Table VII. Absolute event rates in warfarin-unsuitable patients randomized to receive aspirin.
Event Annualized Event Rate (per 100 Patient-Years)
Ischemic or unspeciﬁed stroke 3.453
Intracranial hemorrhages 0.322
Other major bleeds excluding intracranial hemorrhages 0.887
Clinically relevant nonmajor bleeds 2.936
Myocardial infarction 1.110
CV hospitalizations unrelated to stroke or MI 13.571
CV ¼ cardiovascular; MI ¼ myocardial infarction.
Clinical Therapeuticsembolism, nonbleeding, and nonmyocardial infarc-
tion mortality rates of 3.5935 per 100 patient-years
(n ¼ 114) versus apixaban, which had a mortality rate
of 2.9668 per 100 patient-years (n ¼ 94). This yielded
a slightly greater HR of 1.212 (95% CI, 0.922–
1.593).
Absolute Annualized Event Rates in Warfarin-
Unsuitable Patients Randomized to Aspirin Arm
Supplemental Table VII describes annualized event
rates for various events of interest in warfarin-
unsuitable patients randomized to the aspirin arm.210.e20REFERENCES
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